Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Emami Ltd Interim / Quarterly Report 2021

May 25, 2021

61637_rns_2021-05-25_10fae57b-0ca1-4c9a-b92b-dc90d44b203c.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

==> picture [291 x 31] intentionally omitted <==

==> picture [60 x 53] intentionally omitted <==

==> picture [128 x 19] intentionally omitted <==

Emami continues the momentum of its strong Sales & Profit growth in Q4FY21

Q4FY21 HIGHLIGHTS

  • 39% growth in Net Sales. 37% growth in Revenue from Operations

    • Domestic Business Net Sales grew by 44%

o International Business Net Sales grew by 28%

  • Strong improvement in Profit, notwithstanding input cost pressure

    • EBIDTA grew by 65%. Margins improved by 380 bps.

    • PAT grew by 3.8x. Margins improved by 760 bps.

    • Cash Profits* grew by 57%. Margins improved by 300 bps.

Pace of Innovation continues in Q4FY21

  • Launched Zandu Chyawanprash with Jaggery (Gur) during the quarter. Also launched Kesh King Ayurvedic Onion Range and Navratna Gold Ayurvedic Cool Oil in the e-commerce channel.

Cash Profit= PAT+ Depreciation & Amortization

Kolkata, Tuesday 25[th] May 2021: The Board of Directors of Emami Limited met on Tuesday, 25[th] May 2021 to consider the Audited financial results of the company for the fourth quarter and full year ended 31[st] March 2021.

Building on improved demand scenario coupled with increased focus on Healthcare and Hygiene products, the Company has consistently delivered broad based growth across brands, channels and businesses in Q4FY21. The quarter witnessed strong growth all around, with 44% growth in Domestic business and 28% growth in International Business. Both Net sales and revenues grew by 39% and 37% respectively on a consolidated level over previous year. Further, all major brands grew handsomely by more than 30% during the quarter.

Both the urban and rural markets performed well during the quarter and the Retail channel also picked up momentum. While Modern trade grew by 46%, ecommerce continued its robust run growing by 3x. In Q4FY21, ecommerce business increased its contribution by 200 bps to ~4% of domestic revenues.

During the quarter, the company introduced new variants of its existing brands for both general and ecommerce channels. Zandu Chyawanprash introduced a jaggery-based variant of Zandu

==> picture [60 x 53] intentionally omitted <==

==> picture [128 x 19] intentionally omitted <==

Chyawanprash for the first time in India. The company also launched Kesh King Ayurvedic Onion Range and Navratna Gold Ayurvedic Cool Oil, specifically for the e-commerce channel.

The Company’s International business grew by 28% on back of robust performance in markets of SAARC, GCC & Africa during the quarter. Brands like 7 Oils in One, Creme 21 and Kesh King performed well in the International geographies. The CSD business however declined by 3% during the quarter.

During the quarter, input cost pressure increased due to inflation in key commodities which led to a gross margin decline of 250 bps. However, EBIDTA at Rs. 163 cr grew by 65% and EBIDTA margins at 22.3% grew by 380 bps. PAT at Rs. 88 cr grew by 3.8 times and PAT Margins at 12.0% increased by 760 bps. Cash Profits at Rs. 171 cr too increased by 57% with margins increasing by 300 bps at 23.4%.

For the full year, Consolidated Revenues at Rs. 2,881 cr increased by 8%. Gross margins at 67.7% increased by 70 bps on account of benign raw material prices in the earlier part of the year and stringent cost control measures. EBIDTA at Rs. 883 cr grew by 28%. EBIDTA margins which are at an all-time high of 30.7% grew by 460 bps. PAT at Rs. 454 cr grew by 50% with margins at 15.8% increasing by 440 bps and Cash Profits at Rs. 822 cr also grew by 29% with margins at 28.5% increasing by 440 bps.

The Company also rewarded its shareholders handsomely during the year by declaring two interim dividends of Rs. 4/- each, cumulatively amounting to Rs. 356 cr, i.e. a payout of 78% on PAT and 43% on Cash Profits. The Company also completed Buyback of its shares amounting to Rs. 221 cr (including taxes). Despite these outflows, the Company reported a Net Cash surplus of Rs. 357 cr at the end of the year.

Mr Mohan Goenka, Director, Emami Limited said:

We are very happy to have continued with our growth momentum and consistently delivered broad based growth across brands, channels and businesses and close the fourth quarter with an overall revenue growth of 37% and EBIDTA growth of 65%, despite increase in major input costs in Q4FY21. While rural demand has sustained, urban demand is gradually picking up. Our domestic business grew by 44%, International business by 28% in Q4FY21 and we continued to improve our sales and profitability quarter on quarter.

Mr Harsha V Agarwal, Director, Emami Limited said:

“This quarter’s performance delivering a consistent all-round growth meets with our expectation. All our major brands grew by more than 30% during the quarter with the Healthcare range’s performance leading the growth chart by 67%, followed by Kesh King

==> picture [60 x 53] intentionally omitted <==

==> picture [128 x 19] intentionally omitted <==

which grew by 45%, Pain Management range by 38%, Navratna by 28%, BoroPlus by 4.5 times and Male Grooming range by 26%. Contribution of e-commerce business also increased from 1.7% of Domestic sales in Q4FY20 to 3.7% in Q4FY21. In our International Business, our new brand Creme 21 has consolidated its position and have come out on tops followed closely by 7 Oils in One. During the quarter, we invested in brand building, resulting in 37% growth in our ad spends, which is in line with our sales growth. With our focus on digitization and evolved business strategies, we are confident of continuing the growth momentum in the long run despite the 2[nd] wave of COVID-19”.

About Emami Ltd

Emami: (NSE: EMAMILTD, BSE: 531162) Emami Ltd, founded in 1974, is one of India’s leading FMCG Companies engaged in manufacturing & marketing of personal care & healthcare products.

With over 300 diverse products, Emami’s portfolio includes trusted power brands like Navratna, BoroPlus, Fair & Handsome, Zandu Balm & Mentho Plus. In 2015, the Company acquired the business of ‘Kesh King’ and forayed into the Ayurvedic hair & scalp care segment. In, 2019, the company acquired Creme 21, a German brand with strong roots & brand recall. Emami products are available in over 4.5 million retail outlets across India through its network of ~3250 distributors and its global footprint spans over 60 countries including GCC, Europe, Africa, CIS countries & the SAARC.

Emami has maintained a 10% CAGR in topline for the past 10 years through its consistent business performance. Emami is well known for its aggressive marketing powered by celebrity endorsements like Amitabh Bachchan, Pt Birju Maharaj, Shah Rukh Khan, Salman Khan Hrithik Roshan, Shahid Kapoor, Madhuri Dixit, Katrina Kaif, Kareena Kapoor Khan, Yami Gautam, Kangana Ranaut, Shilpa Shetty, Sonakshi Sinha, Shruti Haasan, Juhi Chawla, Vidyut Jamwal, Kartik Aryaan, Varun Dhawan, Milkha Singh, Tiger Shroff, Sachin Tendulkar, Surya, Jr. NTR, Sania Mirza, Saina Nehwal, Bipasha Basu etc over the years.

With a market cap of around Rs. 23,000 cr, Emami Ltd is the flagship Company of the diversified Emami Group. Please visit www.emamltd.in for further information.

For further information, please contact :

Mahasweta Sen | AVP & Head -Corporate Communications

Email: [email protected] | Handphone: +919836292392